Health Catalyst, Inc. (NASDAQ:HCAT) COO Sells $39,119.59 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.51, for a total transaction of $39,119.59. Following the completion of the transaction, the chief operating officer now owns 91,253 shares of the company’s stock, valued at approximately $685,310.03. This trade represents a 5.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Daniel Lesueur also recently made the following trade(s):

• On Tuesday, November 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $7.70, for a total transaction of $40,109.30.

Health Catalyst Stock Down 6.4 %

HCAT stock opened at $6.89 on Friday. Health Catalyst, Inc. has a 12 month low of $5.42 and a 12 month high of $11.41. The firm has a market cap of $419.24 million, a PE ratio of -5.10 and a beta of 1.36. The firm has a 50 day simple moving average of $7.79 and a 200 day simple moving average of $7.52. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. During the same period in the prior year, the company earned ($0.22) earnings per share. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. Equities research analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on HCAT. Royal Bank of Canada upped their target price on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Piper Sandler restated an “overweight” rating and issued a $12.00 target price (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Evercore ISI upped their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Stephens upped their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus price target of $11.45.

Institutional Investors Weigh In On Health Catalyst

Several hedge funds have recently made changes to their positions in HCAT. Principal Financial Group Inc. lifted its position in shares of Health Catalyst by 6.9% in the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after acquiring an additional 1,907 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Health Catalyst by 9.1% in the 2nd quarter. Rhumbline Advisers now owns 91,111 shares of the company’s stock valued at $582,000 after acquiring an additional 7,589 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in shares of Health Catalyst by 276.3% in the 2nd quarter. Los Angeles Capital Management LLC now owns 213,693 shares of the company’s stock valued at $1,365,000 after acquiring an additional 156,908 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Health Catalyst by 1.3% in the 2nd quarter. Acadian Asset Management LLC now owns 734,257 shares of the company’s stock valued at $4,690,000 after acquiring an additional 9,697 shares in the last quarter. Finally, ClariVest Asset Management LLC lifted its position in shares of Health Catalyst by 1.2% in the 2nd quarter. ClariVest Asset Management LLC now owns 285,627 shares of the company’s stock valued at $1,825,000 after acquiring an additional 3,302 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.